7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

Clinical Definition & NIAID/FAAN Diagnostic Criteria

Anaphylaxis is an acute, life-threatening, multi-system syndrome triggered by the sudden, systemic release of inflammatory mediators (histamine, tryptase, platelet-activating factor, leukotrienes C4/D4/E4, prostaglandin D2) from mast cells and basophils. While classically mediated by allergen-specific immunoglobulin E (IgE), non-IgE-mediated anaphylactoid reactions (e.g., radiocontrast media, vancomycin, opioids) present with clinically indistinguishable physiological collapses and require identical emergency management.

According to the National Institute of Allergy and Infectious Disease / Food Allergy and Anaphylaxis Network (NIAID/FAAN) criteria, anaphylaxis is highly likely when any one of three clinical scenarios is satisfied:

                         NIAID/FAAN DIAGNOSTIC PHENOTYPES
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ CRITERION 1: ACUTE ONSET (Minutes to Hours) WITH SKIN / MUCOSAL SIGNS       │
  │ (Generalized hives, pruritus, flushing, swollen lips/tongue/uvula) PLUS:    │
  │   • Respiratory Compromise (Dyspnea, wheeze, stridor, hypoxemia, PEF drop)  │
  │     OR                                                                      │
  │   • Reduced Blood Pressure / End-Organ Dysfunction (Syncope, hypotonia)     │
  ├─────────────────────────────────────────────────────────────────────────────┤
  │ CRITERION 2: TWO OR MORE RAPID SIGNS AFTER A LIKELY ALLERGEN               │
  │   1. Skin/Mucosal Involvement (Hives, swollen lips, flushing)               │
  │   2. Respiratory Compromise (Stridor, wheezing, cough, hypoxemia)           │
  │   3. Reduced Blood Pressure or Associated Symptoms (Collapse, syncope)      │
  │   4. Persistent Gastrointestinal Cramping / Vomiting / Diarrhea             │
  ├─────────────────────────────────────────────────────────────────────────────┤
  │ CRITERION 3: REDUCED BLOOD PRESSURE AFTER A KNOWN ALLERGEN                  │
  │   • Adults: Systolic BP <90 mmHg OR >30% decrease from baseline             │
  │   • Infants/Children: Low age-specific SBP OR >30% decrease from baseline   │
  └─────────────────────────────────────────────────────────────────────────────┘

---

First-Line Definitive Pharmacotherapy: Epinephrine

Epinephrine (adrenaline) is the undisputed first-line medication for anaphylaxis. There are no absolute contraindications to epinephrine administration in a life-threatening anaphylactic emergency.

Dosing, Formulation & Administration Route

• Drug Concentration: 1 mg/mL (1:1,000 solution) formulation.
• Route of Administration: INTRAMUSCULAR (IM) injection administered into the anterolateral mid-thigh (vastus lateralis).
• Adult Dosing: 0.3 to 0.5 mg IM (0.3 to 0.5 mL of 1 mg/mL solution).
• Pediatric Dosing: 0.01 mg/kg IM (up to a single maximum dose of 0.3 mg), or weight-tiered autoinjectors:
  • Labeled weight bands: 0.1 mg autoinjector for infants 7.5 to 15 kg; 0.15 mg for 15 to 30 kg; 0.3 mg for 30 kg and above.
  • The American Academy of Pediatrics suggests moving to the 0.3 mg device at about 25 kg.
  • Nasal epinephrine (neffy) is an FDA-approved needle-free alternative: 2 mg for patients 30 kg and above (2024) and 1 mg for children 15 to 30 kg (2025). It is useful for patients who will not carry or use a needle device.
• Dosing Frequency: May be repeated every 5 to 15 minutes based on hemodynamic and airway response. Most patients responding to IM epinephrine require 1 to 2 doses.

Pharmacokinetics: Why the Vastus Lateralis is Mandatory

Landmark pharmacokinetic investigations led by Estelle Simons evaluated plasma epinephrine concentrations following different routes and anatomical injection sites:

                     PEAK PLASMA EPINEPHRINE KINETICS (Cmax)
  ┌───────────────────────────────────────────────────────────────────────────┐
  │ Intramuscular Mid-Thigh (Vastus Lateralis): Peak Cmax in ~8 ± 2 minutes   │
  │  • Massive vascularity of vastus lateralis ensures rapid drug uptake      │
  │  • First-line standard of care across all international resuscitation guidelines│
  ├───────────────────────────────────────────────────────────────────────────┤
  │ Subcutaneous (SC) Injection: Peak Cmax in ~34 ± 14 minutes                │
  │  • Delayed, erratic absorption; local alpha-1 vasoconstriction impedes entry│
  │  • Unacceptable therapeutic delay during acute vascular collapse          │
  ├───────────────────────────────────────────────────────────────────────────┤
  │ Intramuscular Deltoid: Slower, erratic absorption compared to thigh       │
  │  • Lower local blood flow compared to vastus lateralis in shock states    │
  └───────────────────────────────────────────────────────────────────────────┘

During anaphylactic shock, cutaneous and subcutaneous blood flow is severely compromised due to peripheral shunting and microvascular collapse. Subcutaneous epinephrine injection triggers intense localized alpha-1 vasoconstriction, trapping the drug in the hypodermis and delaying systemic peak concentrations for over half an hour. Consequently, subcutaneous administration is obsolete and clinically contraindicated in anaphylaxis.

Receptor Pharmacodynamics

Epinephrine is an agonist across alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors, providing comprehensive physiological reversal of every organ system derangement:

1. Alpha-1 Adrenergic Stimulation: Reverses peripheral vasodilation, increases systemic vascular resistance, elevates diastolic blood pressure, and reduces post-capillary venular permeability, rapidly decreasing mucosal edema and relieving laryngeal obstruction.
2. Beta-1 Adrenergic Stimulation: Increases cardiac contractility (positive inotropy) and heart rate (positive chronotropy), restoring forward stroke volume and cardiac output.
3. Beta-2 Adrenergic Stimulation: Produces immediate bronchial smooth muscle relaxation (bronchodilation). Furthermore, beta-2 receptor activation on mast cell and basophil membranes stimulates adenylyl cyclase, elevating intracellular cyclic AMP (cAMP). High cAMP levels directly inhibit further mast cell degranulation, terminating the release of histamine, leukotrienes, and cytokines at the source.

---

Refractory Anaphylaxis & Vascular Collapse Protocols

Refractory anaphylaxis is defined as persistent hypotension, upper airway obstruction, or severe bronchospasm despite 2 to 3 appropriately dosed IM epinephrine injections and initial IV fluid resuscitation.

Pathophysiology of Anaphylactic Shock

Anaphylactic shock is a distributive and hypovolemic crisis. Systemic inflammatory mediators trigger widespread arteriolar dilation and massive post-capillary venular permeability. Up to 35% of the total intravascular circulating blood volume can shift into the interstitial space within 10 minutes, resulting in profound hemoconcentration, decreased venous return, and empty cardiac chambers.

Aggressive Fluid Resuscitation

• Adults: Rapid infusion of 1 to 2 liters of balanced crystalloids (e.g., Lactated Ringer's or Plasma-Lyte) administered via large-bore IV catheters under pressure bags.
• Pediatrics: 20 mL/kg crystalloid boluses repeated up to 40 to 60 mL/kg in the first hour.

Intravenous Epinephrine Continuous Infusion

When hypotension persists despite IM epinephrine and fluid loading, intravenous epinephrine must be started without delay. Intravenous boluses of undiluted 1 mg/mL or 0.1 mg/mL epinephrine can cause lethal ventricular fibrillation, myocardial ischemia, and intracranial hemorrhage; infusions must be diluted and titratable.

• Standard Infusion Concentration: 1 mg epinephrine (1 mL of 1 mg/mL) added to 250 mL of D5W or 0.9% normal saline (concentration = 4 mcg/mL).
• Weight-Based Dosing: 0.1 to 1.0 mcg/kg/minute IV infusion titrated to mean arterial pressure (MAP ≥65 mmHg) and airway improvement.
• Non-Weight-Based Dosing: 1 to 10 mcg/minute IV infusion (starting at 1 to 2 mcg/min and titrating rapidly).

Push-Dose Epinephrine (Bridging Therapy)

Push-dose epinephrine provides immediate, temporary hemodynamic support while an infusion pump and bag are compounded:

• Compounding Protocol: Take 1 mL of cardiac epinephrine 0.1 mg/mL (1:10,000) (which contains 100 mcg) and draw it into a syringe containing 9 mL of 0.9% normal saline. The resulting 10 mL solution has a concentration of 10 mcg/mL.
• Dosing: Administer 10 to 20 mcg IV bolus (1 to 2 mL) every 2 to 5 minutes titrated to blood pressure.

---

Beta-Blocker Associated Anaphylaxis & The Glucagon Protocol

Patients on chronic beta-adrenergic antagonist therapy (e.g., metoprolol, carvedilol, propranolol, atenolol) who experience anaphylaxis present a unique, high-mortality clinical emergency.

                  BETA-BLOCKER OVERRIDE MECHANISM: GLUCAGON
  ┌───────────────────────────────────────────────────────────────────────────┐
  │ Epinephrine ──► Beta-1 / Beta-2 Receptors BLOCKED by Beta-Blockers        │
  │                 (Unopposed alpha-1: Severe Bradycardia & Refractory Shock)│
  ├───────────────────────────────────────────────────────────────────────────┤
  │ Glucagon ─────► Specific Myocardial GLUCAGON RECEPTORS (Non-Adrenergic)   │
  │                 (Directly stimulates Adenylyl Cyclase ──► ↑ cAMP)         │
  │                 (Restores Heart Rate, Inotropy, and Bronchial Relaxation) │
  └───────────────────────────────────────────────────────────────────────────┘

Pathophysiological Dilemma

Competitive beta-receptor blockade prevents epinephrine from stimulating myocardial beta-1 and bronchial/mast-cell beta-2 receptors. Furthermore, administering epinephrine in the presence of severe beta-blockade leaves alpha-1 receptors unopposed, triggering massive peripheral vasoconstriction that can induce severe reflex bradycardia, profound cardiogenic/distributive shock, and fatal cardiovascular collapse.

Glucagon Administration Protocol

• Mechanism: Glucagon binds to independent, non-adrenergic G-protein-coupled glucagon receptors on the myocardium and airway smooth muscle. This bypasses adrenergic receptors entirely to activate adenylyl cyclase directly, increasing intracellular cAMP, augmenting calcium entry, and restoring heart rate, cardiac contractility, and bronchodilation.
• Dosing Regimen:
  • Initial Bolus: 1 to 5 mg IV administered slowly over 5 minutes.
  • Maintenance Infusion: 5 to 15 mcg/minute continuous IV infusion titrated to clinical response.
• Adverse Effects & Essential Precaution: Rapid administration of IV glucagon induces severe nausea and intractable vomiting in almost all conscious patients due to acute relaxation of the lower esophageal sphincter and gastric smooth muscle.
• Aspiration Prevention: Patients receiving IV glucagon must be placed in the lateral decubitus position with active oral suction immediately available at the bedside. Pre-treatment or concurrent administration of IV ondansetron (4 to 8 mg) is recommended.

---

Second-Line Adjuncts & Clinical Misconceptions

Antihistamines and systemic corticosteroids are categorized as second-line adjunctive therapies. A major cause of preventable anaphylaxis fatalities is the inappropriate administration of antihistamines or steroids instead of or prior to epinephrine.

---

Biphasic Anaphylaxis & ED Disposition Protocols

Biphasic Reactions

Biphasic anaphylaxis is defined as the recurrence of systemic anaphylactic symptoms following complete clinical resolution of the initial event without re-exposure to the culprit allergen.

• Incidence: About 5% of anaphylaxis cases in pooled data (reported range roughly 1% to 20%).
• Timeline: Typically manifests within 4 to 12 hours after resolution of the primary episode, though documented cases have occurred up to 72 hours later.
• Independent Risk Factors:
  1. Delayed initial epinephrine administration (>30 to 60 minutes from symptom onset).
  2. Severe initial clinical presentation (hemodynamic shock, wide pulse pressure, respiratory failure).
  3. Requirement for more than one dose of epinephrine during initial resuscitation.
  4. Prior history of biphasic anaphylaxis.

Observation Duration & Discharge Bundle

• Observation Guidelines: Patients with moderate-to-severe anaphylaxis or those requiring multiple epinephrine doses must be observed in the emergency department for a minimum of 4 to 8 hours from symptom resolution. Patients who experienced refractory shock requiring IV infusions should be admitted to an ICU or step-down unit for 24 hours of observation.
• Discharge Prescription: Patients must be discharged with a prescription for two (2) epinephrine autoinjectors (e.g., 0.3 mg or 0.15 mg), a personalized written anaphylaxis action plan, hands-on demonstration of device technique, education on trigger avoidance, and a referral to an allergy and immunology specialist.